Purpose of this Study
We are doing this study to find out if an experimental drug called RO7589831 (the study drug) is a safe and effective option for cancers with solid tumors. We also want to find out what the best dose of the study drug is in this study.
Who Can Participate?
Eligibility
Adults ages 18+ who:
- Are diagnosed with advanced cancer that worsened after at least 1 prior line of standard therapy
- Have had a tumor sample test positive for microsatellite instability or mismatch repair deficiency
For more information about this study, please contact the study team at 919-668-1861 or gi-oncology-cru@dm.duke.edu.
- Are diagnosed with advanced cancer that worsened after at least 1 prior line of standard therapy
- Have had a tumor sample test positive for microsatellite instability or mismatch repair deficiency
For more information about this study, please contact the study team at 919-668-1861 or gi-oncology-cru@dm.duke.edu.
What is Involved?
If you choose to join this study, you will:
- Take the study drug every day (it is taken by mouth)
- Have your tumor biopsied
- Give blood and urine samples
- Have regular CT or MRI scans
- Take the study drug every day (it is taken by mouth)
- Have your tumor biopsied
- Give blood and urine samples
- Have regular CT or MRI scans
Study Details
Full Title
[BP44474] A phase I, open-label study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor activity of RO7589831 in participants with advanced solid tumors harboring microsatellite instability (MSI) and/or deficient mismatch repair (dMMR)
Principal Investigator
John
Strickler
Protocol Number
PRO00113812
NCT ID
NCT06004245
Phase
I
Enrollment Status
OPEN TO ACCRUAL